Our News
Alnylam Publishes 2023 Corporate Responsibility Report
May 7, 2024
Corporate Responsibility (CR) is a core focus at Alnylam, revolving around our global theme: "Accepting Challenges to Improve the Health of Humanity." This theme not only informs our CR strategy but also guides how Alnylam operates at every level across interconnected pillars crucial to our daily activities and external impact – Patients, Science, Employees, Communities, Planet, and Governance.
As we grow and progress in our quest to realize the promise of RNAi, we continue to expand our leadership and impact as a responsible corporate citizen. I am proud of the broad range of initiatives highlighted in this report, which reflect our efforts to continually increase the value that we contribute to society." – Dr. Yvonne Greenstreet, Alnylam CEO
With the release of our 2023 Corporate Responsibility Report, we have passed another milestone along our CR journey, achieved through the diligent efforts of our CR Steering Committee and CR Pillar Working Groups, each comprised of employees from across the globe. Together, these teams have established objectives, evaluated past goals, refined our priorities, and have been instrumental in identifying key performance indicators to help us monitor our progress.
As we continue to evolve our CR program, we are committed to collecting and disclosing data that is material to our business and our stakeholders.
Key highlights from the 2023 report include:
- Updates on our continuous work to increase clinical trial diversity, including a new partnership with the Novartis led Beacon of Hope Initiative, a 10-year collaboration with Historically Black Colleges and Universities (HBCUs).
- Expansion of and progress updates from Alnylam Challengers, our global health equity community impact program.
- Snapshot of our partnerships with global organizations pioneering genetic sequencing to disrupt traditional drug discovery and development.
- Three years of comparative data on energy, water usage and waste management to further our commitment to transparency.
- 3rd party verification of scope 1, 2 and select scope 3 greenhouse gas (GHG) emissions.
- Expanded patient data reflecting the integration of our Patient Access Philosophy.
- New employee demographic data disclosures and information on pay equity.
Our 2023 report provides more details about the actions we've taken thus far, as well as the goals we've set for the year ahead. With the help of every employee, we are excited to continue our momentum.
We invite you to download our 2023 Corporate Responsibility Report to read more about our efforts and progress.
FOLLOW US
